Adaptimmune Quarterly report pursuant to Section 13 or 15(d)

Loss per share (Tables)

3 Months Ended

Mar. 31, 2019

The numerator for the basic and diluted income (loss) per share is as follows (in thousands):


	Three months ended
	March 31,
	2019		2018
Net income (loss) attributable to ordinary shareholders	$	(27,412)	$	(21,078)
Numerator for basic income (loss) per share		(27,412)		(21,078)
Numerator for diluted income (loss) per share		(27,412)		(21,078)

The denominator for the basic and diluted income (loss) per share is as follows:


	Three months ended
	March 31,
	2019	2018
Denominator for basic income (loss) per share - Weighted average shares outstanding	627,945,243	562,381,995
Effect of dilutive securities:
Employee stock options	103,848,778	89,203,915
Denominator for diluted income (loss) per share	731,794,021	651,585,910